Narrow-moat Boston Scientific’s BSX long-awaited clinical data on its Farapulse pulsed field ablation, or PFA, device for atrial fibrillation didn’t disappoint, and we’ve raised our fair value ...
BTIG analysts remain high on Boston Scientific (NYSE:BSX) following meetings with the company's management this week.
Boston Scientific Corp BSX will present results from ADVENT pivotal trial for its Farapulse Pulsed Field Ablation (PFA) system at the 2023 European Society of Cardiology Congress on 27 August. ADVENT ...
Boston Scientific Corporation BSX recently presented positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE Pulsed Field Ablation (PFA) System -- a nonthermal treatment in ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and effectiveness of the FARAPULSE Pulsed Field Ablation (PFA) System as a first-line ...
MARLBOROUGH, Mass., Dec. 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ ...
Boston Scientific just became the second company to cross the FDA finish line in the pulsed field ablation (PFA) market. The company's Farapulse PFA system, which was first-to-market in Europe, is one ...
Pulsed-field ablation is a non-thermal method for cardiac ablation that uses strong electrical pulses to selectively destroy cardiac tissue. It is used to treat atrial fibrillation. It is also one of ...
“No one has previously done a large, randomized trial looking at any ablation modality in persistent atrial fibrillation patients as a first-line therapy,” Boston Scientific Chief Medical Officer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results